Houston, TX — Claimants suing Genesis HealthCare — including families pursuing malpractice and wrongful-death cases — are asking a bankruptcy judge to order an independent examination of the company’s sale process, arguing the winning bid may improperly advantage existing insiders at the expense of unsecured creditors.
The motion, filed late last week, challenges the selection of CPE 88988 LLC, a bidder tied to Pinta Capital Partners and entrepreneur Joel Landau, an investor with previous ownership links to Genesis. According to industry reports, claimants say the bid’s insider affiliations warrant heightened scrutiny and may raise conflict-of-interest concerns.
Claimants Say a Stronger Offer Was Overlooked
In their filing, the claimants contend that the chosen bid was accepted over what they describe as a “higher and objectively better” competing offer. They argue that if the insider-backed deal proceeds, unsecured creditors — including injury victims — could see sharply reduced or even minimal recovery given Genesis’s large volume of pending claims.
Public reporting indicates that more than $1 billion in total claims have been asserted against Genesis, spanning malpractice allegations, wrongful-death suits, and commercial liabilities.
To evaluate whether the auction favored insiders, claimants asked the court to appoint retired bankruptcy judge Harlin Hale as an independent examiner. His role would be to review the auction, the relationships between bidders, and the broader restructuring strategy.
Lawmakers Enter the Fray
Several federal lawmakers, including Sens. Elizabeth Warren and Richard Blumenthal and Rep. Maggie Goodlander, have filed an amicus brief supporting the request for an examiner. They argue that the court must ensure transparency before approving a sale structure that could allow insiders to regain control while leaving victims without meaningful compensation.
Advocacy groups have similarly warned that the proposed deal could enable Genesis to offload substantial liability exposure through bankruptcy while continuing operations under aligned ownership — a structure they say demands fuller investigation.
Legal Tensions as Hearing Approaches
A hearing to consider approval of the sale has been scheduled for Dec. 10, 2025, according to public court notices. Claimants have asked the court to postpone that hearing pending completion of an independent review.
Genesis, meanwhile, has accused the claimants of improperly disclosing auction materials to the press and has warned it may seek sanctions or other remedies — a sign of escalating tensions as the sale process nears a critical juncture.
The examiner request highlights a central dispute in the bankruptcy: whether the restructuring plan preserves Genesis’s future at the expense of those alleging harm, or whether the court will require a more transparent accounting before allowing the insider-backed deal to advance.
Discover more from Skilled Care Journal
Subscribe to get the latest posts sent to your email.
